Skip to main content
PMC home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1987 Feb;79(2):478–482. doi: 10.1172/JCI112837

Potent in vitro and in vivo antitoxoplasma activity of the lipid-soluble antifolate trimetrexate.

C J Allegra, J A Kovacs, J C Drake, J C Swan, B A Chabner, H Masur
PMCID: PMC424107  PMID: 2948969

Abstract

Trimetrexate, a highly lipid-soluble quinazoline antifolate now undergoing trials as an anticancer agent, was found to be a potent inhibitor of the dihydrofolate reductase (DHFR) isolated from Toxoplasma gondii. The concentration required for 50% inhibition of protozoal DHFR was 1.4 nM. As an inhibitor of this enzyme, trimetrexate was almost 600-fold (amount of antifolate required to inhibit catalytic reaction by 50%) and 750-fold (inhibition constant) more potent than pyrimethamine, the DHFR inhibitor currently used to treat toxoplasma infection. When the protozoan was incubated with 1 microM trimetrexate, the drug rapidly reached high intracellular concentrations. Since toxoplasma organisms lack a transmembrane transport system for physiologic folates, host toxicity can be prevented by co-administration of the reduced folate, leucovorin, without reversing the antiprotozoal effect. The effectiveness of trimetrexate against toxoplasma was demonstrated both in vitro and vivo. Proliferation of toxoplasma in murine macrophages in vitro was completely inhibited by exposure of these cells to 10(-7) M trimetrexate for 18 h. When used alone, trimetrexate was able to extend the survival of T. gondii-infected mice.

Full text

PDF
478

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BERTINO J. R., FISCHER G. A. TECHNIQUES FOR STUDY OF RESISTANCE TO FOLIC ACID ANTAGONISTS. Methods Med Res. 1964;10:297–307. [PubMed] [Google Scholar]
  2. Burchall J. J., Hitchings G. H. Inhibitor binding analysis of dihydrofolate reductases from various species. Mol Pharmacol. 1965 Sep;1(2):126–136. [PubMed] [Google Scholar]
  3. Cheng Y., Prusoff W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol. 1973 Dec 1;22(23):3099–3108. doi: 10.1016/0006-2952(73)90196-2. [DOI] [PubMed] [Google Scholar]
  4. DeLean A., Munson P. J., Rodbard D. Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves. Am J Physiol. 1978 Aug;235(2):E97–102. doi: 10.1152/ajpendo.1978.235.2.E97. [DOI] [PubMed] [Google Scholar]
  5. Drake J. C., Allegra C. J., Chabner B. A. A re-evaluation of the competitive protein binding assay for methotrexate binding to dihydrofolate reductase. Biochem Pharmacol. 1986 Apr 1;35(7):1212–1214. doi: 10.1016/0006-2952(86)90166-8. [DOI] [PubMed] [Google Scholar]
  6. Henderson G. B., Zevely E. M. Transport routes utilized by L1210 cells for the influx and efflux of methotrexate. J Biol Chem. 1984 Feb 10;259(3):1526–1531. [PubMed] [Google Scholar]
  7. Jones T. C., Yeh S., Hirsch J. G. The interaction between Toxoplasma gondii and mammalian cells. I. Mechanism of entry and intracellular fate of the parasite. J Exp Med. 1972 Nov 1;136(5):1157–1172. doi: 10.1084/jem.136.5.1157. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kamen B. A., Eibl B., Cashmore A., Bertino J. Uptake and efficacy of trimetrexate (TMQ, 2,4-diamino-5-methyl-6-[(3,4,5-trimethoxyanilino)methyl] quinazoline), a non-classical antifolate in methotrexate-resistant leukemia cells in vitro. Biochem Pharmacol. 1984 May 15;33(10):1697–1699. doi: 10.1016/0006-2952(84)90298-3. [DOI] [PubMed] [Google Scholar]
  9. Kovacs J. A., Hiemenz J. W., Macher A. M., Stover D., Murray H. W., Shelhamer J., Lane H. C., Urmacher C., Honig C., Longo D. L. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med. 1984 May;100(5):663–671. doi: 10.7326/0003-4819-100-5-663. [DOI] [PubMed] [Google Scholar]
  10. Matthews D. A., Bolin J. T., Burridge J. M., Filman D. J., Volz K. W., Kraut J. Dihydrofolate reductase. The stereochemistry of inhibitor selectivity. J Biol Chem. 1985 Jan 10;260(1):392–399. [PubMed] [Google Scholar]
  11. McCutchan T. F., Welsh J. A., Dame J. B., Quakyi I. A., Graves P. M., Drake J. C., Allegra C. J. Mechanism of pyrimethamine resistance in recent isolates of Plasmodium falciparum. Antimicrob Agents Chemother. 1984 Nov;26(5):656–659. doi: 10.1128/aac.26.5.656. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Moran R. G., Colman P. D. A simple procedure for the synthesis of high specific activity tritiated (6S)-5-formyltetrahydrofolate. Anal Biochem. 1982 May 1;122(1):70–78. doi: 10.1016/0003-2697(82)90252-4. [DOI] [PubMed] [Google Scholar]
  13. Myers C. E., Lippman M. E., Elliot H. M., Chabner B. A. Competitive protein binding assay for methotrexate. Proc Natl Acad Sci U S A. 1975 Sep;72(9):3683–3686. doi: 10.1073/pnas.72.9.3683. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Stone S. R., Morrison J. F. Mechanism of inhibition of dihydrofolate reductases from bacterial and vertebrate sources by various classes of folate analogues. Biochim Biophys Acta. 1986 Feb 14;869(3):275–285. doi: 10.1016/0167-4838(86)90067-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES